Results 231 to 240 of about 204,052 (290)

Stridor Is an Independent Risk Factor for Mortality and Disease Progression in Patients with Multiple System Atrophy

open access: yesMovement Disorders, EarlyView.
Abstract Background and aim Stridor and sleep apnea syndrome (SAS) are common in multiple system atrophy (MSA). Retrospective cohort studies have yielded conflicting results regarding the consequences of stridor and SAS on the disease course. This study aimed to assess the prognostic significance of stridor and SAS, as well as the potential survival ...
Pauline Dodet   +18 more
wiley   +1 more source

Sleep improvement strategies for people with vision impairment: a scoping review. [PDF]

open access: yesBMJ Open
Leonard-Hawkhead B   +5 more
europepmc   +1 more source

Polyelectromyography Under Propofol to Differentiate Functional from Idiopathic Dystonia: A Pilot Study

open access: yesMovement Disorders, EarlyView.
Abstract Background Functional dystonia (FD) is one of the most diagnostically challenging functional movement disorders. Phenomenological features often lack specificity, as many are also observed in idiopathic dystonia (ID) and validated biomarkers to distinguish FD from ID are currently unavailable Objective To investigate potential differences in ...
Roberto Eleopra   +17 more
wiley   +1 more source

Detrusor Overactivity and Urodynamics

open access: yesNeurourology and Urodynamics, EarlyView.
ABSTRACT While overactive bladder (OAB) is a clinical diagnosis, detrusor overactivity is identified through urodynamic testing. UDS is usually considered when primary treatment for OAB fails, because UDS is expensive, time consuming, invasive, and sometimes inaccurate, and it is not considered to influence treatment strategy substantially.
Laura N. Nguyen, Geneviève Nadeau
wiley   +1 more source

Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT

open access: yesObesity, EarlyView.
ABSTRACT Objective This post hoc analysis assessed psychiatric changes with tirzepatide in adults with obesity, without known major psychopathology, from SURMOUNT‐1, SURMOUNT‐2, and SURMOUNT‐3. Methods In participants (N = 4056) treated with tirzepatide (5/10/15 mg or maximum tolerated dose 10/15 mg) versus placebo, depressive symptoms and suicidal ...
Thomas A. Wadden   +6 more
wiley   +1 more source

Unrecognised sleep disturbances in patients with cirrhosis diagnosed with a portable electroencephalogram device. [PDF]

open access: yesBMJ Health Care Inform
Uchiyama A   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy